Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 35876
Special Issue Editor
“Cancer and adaptive immune response” team, INSERM Research Center LNC-UMR1231, University of Bourgogne-Franche-Comté, Dijon, France
Interests: cancer; immunology; immunotherapy; immunogenic chemotherapies; immunomonitoring
Special Issue Information
Dear Colleagues,
Inhibitory antibodies targeting the PD-1/PD-L1 pathway are now widely used in different types of cancers such as melanoma, lung, head and neck, kidney, and some hematological malignancies. The medical advances made possible by these new drugs are undeniable, however, a significant number of patients do not benefit from this therapy due to the intrinsic or acquired resistance of their tumor to PD-(L)1 inhibition. The biological mechanisms associated with this resistance is increasingly well documented, and we now know that the quality and the quantity of immunological infiltrates are not the same from one cancer to another. It is precisely this heterogeneity that partly determines the degree of efficacy of a PD-(L)1 blockade.The objective of this Special Issue entitled “Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness” is to highlight original research related to the identification of synergistic therapeutic combinations with anti-PD-(L)1 that take into account the tumor immune context. Studies that describe strategies to sensitize “cold” (immunogenic drugs, vaccination, PRR agonists) and “immuno-excluded” tumors (modulators of fibrosis, angiogenesis, etc.), or a strategy to bypass acquired resistance in previously sensitive tumors are particularly appreciated.
Keywords
- cancer immunology
- PD-(L)1 blockade
- therapeutic associations
- immunogenic drugs
- tumor microenvironment modulators